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Abstract 
Purpose: To determine the prevalence of drug therapy problems (DTPs), identify the types of DTPs 
and assess outcomes of DTP interventions among renal patients receiving care in three Nigerian 
tertiary hospitals. 
Methods: This prospective descriptive study was conducted in nephrology units of three tertiary 
hospitals in Nigeria, based on recommendations of working conference of the Pharmaceutical Care 
Network Europe, version 6.2 while the reviews, classification of DTPs and principles of drug use in 
chronic kidney diseases (CKD) were based on evidence-based clinical guidelines and standards of 
practice (Kidney Disease: Improving Global Outcomes (KDIGO).  
Results: Out of 234 DTPs identified, 90 (38.46%) had drug choice problem, 86 (36.75%), had problems 
of drug interactions; 47(20.09%), had dosing problem, while 11 (4.70%) had drug use problem. Clinical 
interventions (459) were undertaken at prescriber level (78; 16.99%); patient/carer level (211, 46.00 %) 
and drug level (170, 30.04 %). Pharmacists recommended 376 of the interventions for approval, out of 
which 310 (67.54%) were approved. Amongst the DTPs indentified, 47.86 % were successfully 
resolved. 
Conclusion: Drug therapy problems among renal patients were high. Inappropriate drug selection and 
drug interactions were the commonest drug therapy problems. The acceptance of pharmacists’ 
interventions by prescribers was appreciable.  
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Medications intended for the treatment, 
prophylaxis or diagnosis of medical conditions 
may have negative effects on patients if not used 
appropriately. Over the years, there have been 
numerous reports of incidence, prevalence, and 
preventability of drug-related hospital admissions 
[1-3], medication error-related deaths [4], and 
adverse drug events in in-patient and out-patient 
settings [5-7]. Drug‑related problems are 
common in hospitalized patients and can 
interfere with the achievements of desired 
therapeutic outcomes [8]. These problems can 
potentially have an impact on desired health 
outcomes [9]. Due to their training, pharmacists 
can play an important role in identifying these 
drug therapy problems (DTPs), resolving actual 
DTPs and preventing potential DTPs through 
careful pharmaceutical practices. There is 
increasing evidence that participation and 
interventions of clinical pharmacists in health 
care have a positive influence on clinical practice 
[10]. In a number of studies, clinical pharmacists 
have been shown to reduce DRPs in the in-
Adibe et al 
Trop J Pharm Res, March 2017; 16(3): 698  
 
patient settings [11]. Some publications have 
evaluated the impact of drug errors identified or 
intercepted by pharmacists in emergency 
departments [12-14], and in in-patient medical 
and surgical wards [15,16]. 
 
In CKD, the number and complexity of drugs 
increase with the progression of the disease and 
can result in a high risk of non-compliance and 
adverse drug reactions. Moreover, CKD patients 
are more at risk of iatrogenic renal failure than 
non-CKD patients (15.3 % vs. 5.3 %, 
respectively) when admitted to an intensive care 
unit [17]. Several studies have shown that 
patients with end-stage renal disease (ESRD) 
are among those at high risk for DTPs [18,19].  
 
The objectives of this study were to determine 
the prevalence of DTPs, identify the types of 
DTPs, and assess the outcomes of DTP 
interventions among renal patients receiving care 




Study design and setting 
 
This prospective descriptive study was 
conducted in nephrology unit of University of 
Nigeria Teaching Hospital (UNTH), Enugu; 
Nnamdi Azikiwe Teaching Hospital, Nnewi and 
Enugu State University Teaching Hospital. These 
are tertiary hospitals that serve as referral 
centres to most of the hospitals, in particular, in 
South-Eastern geo-political zone of Nigeria. 
Ethical clearance of the study was obtained from 





The study included all renal patients who were 
diagnosed with acute renal failure, chronic renal 
failure and other kidney related diseases; 18 
years and above, with or without co‑morbidities, 
and on admission to the medical ward for kidney-
related problems from October, 2014 to March, 
2015.  
 
Instruments for study 
 
This study protocol was based on the 
recommendation made during the working 
conference of the Pharmaceutical Care Network 
Europe, a classification scheme constructed for 
drug related problems (DRPs, V6.2) [20].  
 
The questionnaire used in this study had 
information on the patient’s demographic 
characteristics, including age, sex, and medical 
history, drugs administered to the patient during 
the hospitalization period: Drug name, indication, 
dose, schedule, duration, and monitoring, stage 
of CKD, associated co-morbidities, length of 
hospital stay, and number of drugs prescribed, 





Identification and classification of potential and 
actual DRPs using appropriate guidelines was 
assessed by 3 clinical pharmacists through 
review and analyses of all medication orders, 
administration sheets, laboratory and diagnostic 
test results and pathophysiological status. 
Patients were interviewed for relevant 
information for the study. The reviews, 
classification of DTPs and principles of drug use 
in the CKD were based on evidence-based 
clinical guidelines and standards of practice 
[21,22]. These guidelines have sections for use 
of drug in patients with CKD in reference to other 
co-morbidities, CKD progression/staging and 
dosage adjustment charts and DTPs in CKD for 
individual drugs or groups of drugs. 
 
Drug-drug interactions were assessed using 
RxList drug interaction platform [23]. The RxList 
identifies how the number of interactions in a 
prescription and rates them into the following 
categories: 
 
a) Contra-indicated: Never use this 
combination of drugs because of high risk 
for dangerous interaction 
b) Serious: Potential for serious interaction; 
regular monitoring by your doctor required 
or alternative medication may be needed 
c) Significant: Potential for significant 
interaction (monitoring by your doctor is 
likely required) 
d) Minor: Interaction is unlikely, minor, or non-
significant 
 
Each patient’s drug therapy was routinely 
monitored in every follow-up appointment and 
the DRPs were identified, discussed, and 
documented by the panel. The DTPs and other 
medical related matters were unanimously 
agreed upon during a round table discussion by 
panel members (differences were resolved by 
consensus). Intervention involved discussion of 
resolution of the problem with the prescribers, 
counselling and educating the patients as 
appropriate and change or discontinuation of the 
drug. Drug therapeutic problem charts were 
collected, analyzed, and categorized into types of 
problems, causes of problems, interventions, and 
outcomes of interventions. The medication 
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therapy review was tailored to the individual 
problems of the patient at each encounter. 
Following identification of any DTPs, an 
intervention was proposed to the patient, or the 
physician or other healthcare professionals, or 
both, as appropriate so as to optimize therapy. 
The communication of appropriate information to 
the physician or other healthcare professional 
including consultation on the selection of 
medications, correct dosage regimens, 
suggestions to address medication problems, 





The data were collated and entered into version 
21 of SPSS (SPSS Inc. Chicago) and Microsoft 
2007 Excel package for analysis. Descriptive 
statistics was done and continuous variables 




Patients socio-demographic characteristics 
 
A total of 287 patients with renal illnesses were 
followed for five months and assessed for DTPs. 
More than half of the patients were above 50 
years old (165, 57.49 %), out of which 171 (59.58 
%) were female. Majority of patients were 
married (239, 83.28 %) and about one third of 
them earned less than ₦18, 000 monthly (Table 
1). 
 
Patients’ clinical variables  
 
The clinical features of the patients showed that 
mean serum creatinine, Glomerular Fitration 
Rate (GFR) and hospital stay were 1.34 ± 0.32 
mg/dl, 52.55 ± 14.31 ml/min/1.73 m2 and 16.24 ± 
4.26 days, respectively. The number of patients 
with CKD stages G3 to 5, was 208 (72.48 %). A 
total of 484 co-morbidities (mean: 1.69 ± 0.12) 
were documented, with hypertension and 
diabetes accounting for about two-thirds of the 
co-morbid conditions. Most of the patients (197, 
68.64 %) had 2 or 3 co-morbid conditions (Table 
2). 
 
The total number of drugs received by patients 
was 831 and the number of drugs in the 
prescriptions of most patients (52.96%) ranged 
from 3 to 5 with an average of 2.90 ± 1.03 per 
patient. The number of drugs with restriction in 
renal impairment (RI) was 209, with an average 
of 0.73 ± 0.13 drugs per patient (Table 3). 
 
Amongst the 201 patients with DTPs, 234 DTPs 
were identified in following descending order of 
their prevalence ‘drug choice problem’: 90 (38.46 
%); ‘drug interactions’: 86 (36.75 %); ‘dosing 
problem’ 47 (20.09 %); drug use problem: 11 
(4.70%) and adverse drug reaction: 0 (0.00%). 
The detailed results showed that top specific 
causes of DTPs were ‘potential drug interactions 
(36.75 %) and ‘drug dose too high or dosage 
regime too frequent’ (Table 4). 
 
Table 1: Patients socio-demographic characteristics 
 
Characteristics Frequency Percentage 
Hospitals N =287  
UNTH 137 47.74 
NAUTH 86 29.96 
ESUTH 63 22.30 
Age (Years) N = 287  
Age (mean ± SD) 72.34 ± 7.56  
18 – 35  33 11.50 
36 – 50  89 31.01 
51 -64  103 35.89 
65 - 69 36 12.54 
70 to 80  18 6.27 
80 and above 8 2.79 
Gender N=287  
Male  116 40.42 
Female 171 59.58 
Marital Status N = 287  
Single 48 16.72 
Married 239 83.28 
Economic Status N = 287  
≤ 18,000 Naira 96 33.45 
19 – 50,000 Naira 88 30.66 




˃ 100,000 Naira 32 11.15 
Employment Status N = 287  
Student 13 4.53 
Self-employed 148 51.57 
Civil servant 89 31.01 
Retired  37 12.89 





Primary school 32 11.15 
Secondary School  146 50.87 
Tertiary Education 62 21.60 
UNTH, University of Nigeria Teaching Hospital; 
NAUTH, Nnamdi Azikiwe University Teaching 
Hospital; ESUTH, Enugu State University Teaching 
Hospital 
 
A total of 459 clinical interventions were 
undertaken at three levels of the intervention: 
prescriber level: 78 (16.99 %); patient/career 
level: 211 (46.00 %) and drug level: 170 
(30.04%). Out these, ‘prescriber informed only’ 
(47, 60.26 %), ‘patient (medication) counselling’ 
(111, 52.61 %) and ‘dosage changed’ (84, 49.41 
%) were the most recommended for intervention 
at each level. Out of the 459 interventions, 376 
(81.91 %) were recommended for approval from 
the prescribers, out of which 310 (67.54 %) were 
approved (Table 5). 
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Of the 234 DTPs identified, ‘problems totally 
solved’ was 112 (47.86 %), ‘partially solved’ was 
42 (17.95%), ‘problem not solved due to lack of 
cooperation of the patient’ was  12 (5.13%), 
‘problem not solved due to lack of cooperation of 
prescriber’ was 36 (15.38%) and ‘outcomes not 
known’ was 32 (13.68 %), Table 5. 
 
Table 2: Patient clinical characteristics  
 
Variables  Mean ± SD 
Weight (kg) 64.21 ± 13.45 
Height (m) 1.52 ± 0.23 
BMI (Kg/m2) 26. 76 ± 2.44 
SBP (mm Hg) 138.67 ± 8.32 
DBP (mm Hg) 87.23 ± 7.65 
Creatinine (mg/dl) 1.34 ± 0.32 
GFR (ml/min/1.73 m2) 52.55 ± 14.31 
Mean Hospital stay (days) 16.24 ± 4.26 
CKD Stage  n (%) 
   G1 29 (10.10) 
   G2 50 (17.42) 
   G3a 131 (45.64) 
   G3b 44 (15.33) 
   G4 21 (7.32) 
   G5 12 (4.18) 
*Co-morbidity   (n=484) n (%) 
Diabetes 156 (32.23) 
Hypertension 203 (41.94) 
CHF 32 (6.61) 
Dyslipidemia 43 (8.88) 
Hypo/Hyper Thyrodism 9 (1.86) 




Others 12 (2.48) 
*Total number of co-morbidity  484 
Average number of 
comorbidity per patient (Mean 
± SD) 
1.69 ± 0.12 
Number of co-morbid 
conditions  
n (%) 
   0 or 1 62 (21.60) 
   2 or 3 197 (68.64) 
   4 and above 28 (9.79) 
Haemodialysis  
   Yes 8 (2.79) 
   No 279 (97.21) 
*Some patients had more than one comorbidity. 
Abbreviations: BMI = Body Mass Index, SBP = systolic 
blood pressure, DBP = diastolic blood pressure; GFR 




This study has revealed a very high proportion 
(70.03%) of CKD patients with DRPs. Out of the 
67.54 % of interventions by pharmacist approved 
by a panel,  47.86 % of the DTPs identified were 
successfully resolved. This high proportion of 
DTPs might be due to relatively older population 
involved in the study, as well as severe CKD and 
multiple co-morbidities among the renal patients. 
 
Increasing age causes increasing vulnerability to 
diseases and, in the elderly, the tendency to 
acquire multiple and chronic diseases. This 
population therefore is prescribed and uses more 
drugs than younger populations. In addition, 
multiple complaints, atypical disease 
presentation and physician prescribing habits 
and practices have resulted in the use of multiple 
drugs by these patients [24]. Age is one of the 
most important underlying risk factors for CKD, 
often compounded by the presence of other co-
morbidities such as diabetes, hypertension and 
vascular disease. Among healthy individuals, 
creatinine clearance peaks at approximately 120-
130 mL/min/1.73m2 at age 30 years and then 
declines by about 8 mL/min/1.73m2 per decade 
[21].This result is in agreement with the findings 
in an earlier study [25], which showed that 
majority of patients with DTP were 60 years and 
above. 
 
Most of the patients in this study had CKD stage 
3-5 which requires a therapeutic intensification to 
slow the progression of the disease, prevent risk 
of acute kidney injury and treat co-morbidities, 
particularly cardiovascular risk factors [26]. In 
doing these, there is need to pay close attention 
on the GFR of the patients, to make sure the 
CKD stage does not go beyond G2: this study 
had shown a significant likelihood of increase in 
the number of DTPs by 6.52 for every additional 
deteriorating stage, provided the patients are of 
the same in other variables. 
 
More than one-quarter of the patients had at 
least 4 co-morbidities and about two-thirds 
received at least 3 medications. While no specific 
number of medications has been established to 
define polypharmacy, some have arbitrarily 
suggested cut-off points of 3 to 5 drugs per 
patient [27]. Our results appear to conform with 
this, since 14.63% of the patients received 6 or 
more drugs. In addition, the patients included in 
this investigation had several risk factors for 
polypharmacy, including older age, renal 
disorders, and poorer health [27]. 
 
This revelation underscores the need for extra 
vigilance while reviewing patient’s drugs as this 
could increase their DTPs and cost. A total of 
234 drug therapy problems (DTPs) were 
identified which resulted from drugs prescribed 
during the study. This is considered high. 
Although Ramalho de Oliveira et al. [28] 
identified 38,631 DTPs over a period of 10 years,  
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Table 3: Prescription parameters 
 
Prescription parameter n, n(%), Mean ± SD 
*Total number of drugs prescribed  (n) 831 
Average number of drugs per patient  (Mean±SD) 2.90 ± 1.03 
Number of drugs per patient     n (%)  n = 287 
      0-2 93 (32.40) 
      3 to 5 152 (52.96) 
      6 and above 42 (14.63) 
*Total number of drugs with restriction in renal impairment encountered (n) 209 
Drugs with restriction in RI per patient (Mean±SD) 0.73 ± 0.13 
Total number DTPs encountered  (n) 234 
!Total number of patients with DTPs  n(%) 201(70.03) 
Average number of DTPS per patient (Mean±SD) 0.84 ± 0.08 
Number of DTPs per patient     n (%) n = 287 
    0 53 (18.47) 
    1 or 2 172 (59.93) 
    More than 2 62 (21.60) 
ðPrevalence of drug interactions     n  (%) 86 (36.75) 
RxList Categories of Drug interactions    n(%) n = 86 
    Contra-indicated 38 (44.19) 
    Serious 23 (26.74) 
    Significant 8 (9.30) 
    Minor 17 (19.77) 
Interventions  n(%) n = 459 
Intervention proposed, approved by prescriber  310 (67.54) 
Intervention proposed, not approved by prescriber  66 (14.38) 
Interventions not proposed for approval by prescriber 83 (18.08) 
*Some drug appeared severally: ! potential and actual DTPs; ðThe denominator was 234 (total DTPs 
encountered); RI = renal impairment, DTP = Drug-Therapy problem, DI = Dosing inadequacy, Drugs with 
restrictions (dose adjustment needed in case of renal impairment (RI)) per patient, SD = Standard deviation. 
 
Table 4: Drug therapy problems 
 
Identified drug therapy problem Freqency Percentage 
Adverse reactions (Patient suffers from an adverse drug event)   
   Side effect suffered (non-allergic)  0 0.00 
   Side effect suffered (allergic)  0 0.00 
   Toxic effects suffered  0 0.00 
Drug choice problem (Patient gets or is going to get a wrong (or no drug) drug 
for his/her disease and/or condition) 
 
 
   Inappropriate drug (not most appropriate for indication)  9 3.85 
   Drug treatment more costly than necessary  15 6.41 
   Inappropriate drug form (not most appropriate for indication)  7 2.99 
   Inappropriate duplication of therapeutic group or active ingredient  18 7.69 




   No clear indication for drug use  6 2.56 
   No drug prescribed but clear indication  7 2.99 




   Drug dose too low or dosage regime not frequent enough  9 3.85 
   Drug dose too high or dosage regime too frequent (need dose adjustment 
according to CKD stage) 
 
31 13.25 
   Duration of treatment too short  3 1.28 
   Duration of treatment too long  4 1.71 
Drug use problem (wrong or no drug taken/ administered)   
   Drug not taken/administered at all  11 4.70 
   Wrong drug taken/administered  0 0.00 
Interactions (manifest or potential drug-drug or drug-food interaction)   
   Potential interaction  86 36.75 
   Manifest interaction  0 0.00 
   Therapy failure (reason unknown)  0 0.00 
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Table 5: The DTPs Interventions and Outcomes 
 
¥Interventions Frequency Percentage 
At prescriber level   n = 78  
Prescriber informed only  47 60.26 
Prescriber asked for information  4 5.13 
Intervention recommended, outcome unknown  27 34.62 
At patient/carer level n = 211  
Patient (medication) counseling 111 52.61 
Written information provided only  21 9.95 
Patient referred to prescriber  62 29.38 
Spoken to family member/caregiver  17 8.06 
At drug level n = 170  
Drug changed  11 6.47 
Dosage changed 84 49.41 
Formulation changed 0 0.00 
Instructions for use changed  49 28.82 
Drug stopped  21 12.35 
New drug started  5 2.94 
Side effect reported to authorities  0 0.00 
Outcomes *Outcomes  (n= 234) Freq % 
Not known  Outcome of intervention not known  32 13.68 
Solved  Problem totally solved  112 47.86 
Partially solved  Problem partially solved  42 17.95 
Not solved  Problem not solved, lack of cooperation of patient  12 5.13 
 Problem not solved, lack of cooperation of prescriber  36 15.38 
 Problem not solved, intervention not effective  0 0.00 
 No need or possibility to solve problem  0 0.00 
¥ Interventions were far more than the DTPs identified because a particular DTP may need more than 
one interventions at the same level and other levels to get it resolved, therefore the results were 
analysed according to the levels of the intervention; * Outcomes of 234 DTPs identified and 
intervened 
 
380 DTPs were identified by Nascimento et al 
[29] in a period of two years, and Root et al [30] 
identified 88 DTPs from 40 patients. The 
difference in the number of DTPs encountered is 
probably due to differences in research design in 
terms of patients type, hospital types, duration of 
the studies and nature of data collected.Our 
study showed that mean drug per patient was 
almost 3.0 which is moderate, despite the 
involvement of older population of patients in this 
study. This might be due the fact that most of the 
DTPs encountered in the hospital were not 
recorded or were even missed by pharmacists. 
 
Inappropriate drug selection/dosing problem and 
drug interaction were the major sources of DTPs 
in this study. This result is consistent with a 
number of studies [25,29-33] on DTPs in which 
dosing and/or drug selection problems and drug 
interaction were identified among the major 
forms of DTPs encountered. 
 
A high number of DTPs due to drug 
choice/selection and potential drug interactions 
was recorded in our study. This is similar to 
results obtained in a study conducted by Ismail et 
al [34] which showed 45 % potential drug‑drug 
interactions at pulmonology ward in a tertiary 
care hospital at Peshawar, Pakistan. Our results 
confirm that drug‑drug interaction is a common 
drug therapy problem in both government and 
private hospitals. Khanet al [35] and Alagiriswami 
et al [36] also reported high incidence of drug 
selection problems. 
 
The result of this study also revealed that the 
number of interventions was highest at 
patient/career level, followed by drug level and 
least at prescriber level. This is in agreement 
with the data from a 10-year study by Ramalho et 
al [28] where 80% of DTPs identified in 
Fairview’s MTM programme were resolved at the 
drug or patient level without the direct 
involvement of physician(s). 
 
The trend of recommendation approval found in 
this study is also similar to the results  of Root et 
al [30] where 75 % of the pharmacists’ proposed 
interventions were approved. The lower rate of 
approval of proposed intervention obtained in the 
current study could be as a result of lack of 
collaboration between healthcare providers. 
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Appreciable number of DTPs identified were 
totally resolved. Just like in many studies where 
pharmaceutical care interventions were 
instituded [28-30], DTPs were resolved, patients’ 
conditions were improved and consequently the 
rate of encoutered DTPs in that setting was 
reduced. This is predicated in high acceptance of 
the intervention by the doctors. Pharmacists in 
this hospital should embrace this opportunity to 
reach out to patients who are greatly in need of 
their attention; no matter how busy they are, 
especially in this era of ever expanding role of a 
pharmacist.  
 
The present study has several limitations and the 
results are interpreted in this light. The approach 
used to identify and classify DTPs was based on 
record reviews and explicit criteria of the applied 
guidelines. We could not account for information 
other than those in patients’ records and those 
reported to us. Likewise, we focused on regularly 
scheduled medications rather than on as-needed 
drugs. Thus, our findings may be biased toward 




Drug therapy problems among the renal patients 
studied were high. Inappropriate drug selection 
and drug interactions were the commonest drug 
therapy problems. Pharmacists in Nigerian 
hospitals should always reach out to all patients 
to identify and resolve any drug-related problems 
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